

CEPOP-MAPDA Webinar Series

The event will begin shortly.

The content of this webinar is intended for information only and is not to be considered legal advice.

- **Before we begin:**

- The audio is being streamed through your computer. Please turn your computer speakers on. There is NO call in number.
- You may need to disable pop-up blocking software in order for the presentation software to properly load.
- Review our Tech Tips to enhance your viewing experience and troubleshoot common technical issues.



Confluence of a National Epidemic and Global Pandemic

Confronting Pain and Opioid Use Disorders Amid COVID-19

Access to Medication-Assisted Treatment



Monday, July 27, 2020

3:30pm – 4:30pm



Take Control of Your Console

- All open windows can be adjusted.
- Use the controls to minimize or maximize icons:
- Drag the bottom right hand corner to resize your window:



Today's Agenda

1. A View from Capitol Hill: Congressional Response to MAT Access

The Honorable Paul Tonko (NY-20), *United States House of Representatives*

2. Targeting Policy Changes to Impact Treatment Access and Availability

Claire Brennan, *Section Chief, Liaison Section, Diversion Control Division, DEA*

Anastasia Martin, *Staff Coordinator, Policy Section, Diversion Control Division, DEA*

3. Panel Discussion and Roundtable: Leveraging Technology and Innovation to Drive Evidence-Based Care

- a. **Sam Arsenault, MA**, *Vice President, National Treatment Quality Initiatives, Shatterproof*
- b. **Yuri Maricich, MD, MBA**, *Chief Medical Officer, Pear Therapeutics*
- c. **Mark Parrino, MPA**, *President, American Association for the Treatment of Opioid Dependence (AATOD)*



Mr. Van Ingram

*Executive Director
Kentucky Office of Drug
Control Policy*

The Honorable Paul Tonko

*U.S. House of Representatives
House Committee on Energy &
Commerce*





DEA's Response to COVID-19

DIVERSION CONTROL DIVISION

LIAISON SECTION CHIEF **CLAIRE BRENNAN**

DEA POLICY SECTION STAFF COORDINATOR **ANASTASIA MARTIN**

Drug Enforcement Administration Diversion Control Division



Responsibilities:

- **Schedule** controlled substances
- **Set** production quotas
- **Establish** import and export controls
- **Investigate** DEA registrants to detect diversion
- **Conduct** liaison with industries and associations representing registrants
- **Assist** state and local authorities
- **Represent** the United States on matters related to controlled substances and regulated chemicals at the United Nations
- **Responsible** for drafting and publishing regulations

Executive Order 13891

November 1, 2019



- Requires DEA to obtain permission from the Department of Justice (DOJ) and the Office of Management and Budget (OMB) prior to publishing any public guidance document.
- Prior to this Executive Order DEA could publish guidance documents on their own.



Drug Enforcement Administration

Timeline of COVID-19 Response



January 27, 2020

Secretary of Health and Human Services (HHS) declares the coronavirus a public health threat

January 31, 2020

HHS declares a Public Health Emergency

March 15 – April 20

DEA issues 24 emergency guidance documents to assist practitioners in the treatment of patients

Medication Assisted Treatment Guidance During COVID 19



- Exemption Allowing Alternate Delivery Methods for OTPs - March 16, 2020
- Use of Telephone Evaluations to Initiate Buprenorphine Prescribing - March 31, 2020
- Use of Unregistered Off-Site Locations in MAT - April 7, 2020
- Distributor shipments to NTP's signed delivery exception - April 11, 2020
- Use of Unregistered Off-Site Locations in MAT (Buprenorphine) - April 28, 2020

Drug Enforcement Administration Guidance During COVID-19



- **Suspicious Orders & Due Diligence**
- **Prescriptions**
- **Registration**
- **Quota**
- **National Drug Supply**
- **Electronic Prescribing of Controlled Substances**
- **Telemedicine**
- **Records and Reports**

Drug Enforcement Administration

www.DEADiversion.usdoj.gov



deadiversion.usdoj.gov/coronavirus.html



U.S. DEPARTMENT OF JUSTICE ★ DRUG ENFORCEMENT ADMINISTRATION

DIVERSION CONTROL DIVISION

[HOME](#)[REGISTRATION](#)[REPORTING](#)[RESOURCES](#)[ABOUT US](#)



[COVID-19 Information Page](#)

[COVID-19 Information Page](#)

[Get Email Updates:](#) 

[Suspicious Orders and Due Diligence](#) | [Prescriptions](#) | [Registration](#) | [Quota](#) | [National Drug Supply](#) | [EPCS](#) | [Telemedicine](#) | [Medication Assisted Treatment](#) | [Records and Reports](#) | [Pseudoephedrine & Listed Chemicals](#) | [Contacts](#) | [Important Federal Links](#) | [Important State Links](#)

The mission of Drug Enforcement Administrations (DEA), Diversion Control Division is to prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs.

During this National Emergency the Diversion Control Division is working with our Federal partners including ASPR, FEMA, HHS, FDA, ONDCP, SAMSHA, and members of the White House Task Force; DEA registrants; and representatives of the medical and health-care associations to assure that there is an adequate supply of controlled substances in the United States. The DEA will also work to assure that patients will have access to necessary drug products containing controlled substances.



[Questions and Answers](#)

[Program Description](#)[Contact Us](#)[Customer Service Plan](#)[DEA Forms & Applications](#)[Mailing Addresses](#)[Meetings & Events](#)[Privacy Notice](#)[What's New](#)

Drug Enforcement Administration Prescription Medication Take Back



TakeBackDay.DEA.gov





Leveraging Technology and Innovation to Drive Evidence-Based Care

Cataloging the Impacts of COVID-19 on SUD Treatment Access and Related Policy Interventions

Meet Your Panelists




Samantha Arsenault, MA

*Vice President, National
Treatment Quality Initiatives
Shatterproof*



Yuri Maricich, MD, MBA

*Chief Medical Officer
Pear Therapeutics*



Mark Parrino, MPA

*President
American Association for the
Treatment of Opioid
Dependence (AATOD)*





Roundtable Question & Answer Session

Please submit questions to our panelists using the chat function in the left-hand side of your screen.

If joining via mobile device, email questions to matthew.rubin@faegredrinker.com.

Upcoming CEPOP-MAPDA Webinars

Digital Health and Telemedicine

• Monday, July 27 at 3:00 p.m. ET

Policy Changes to Medication Assisted Treatment

Monday, July 27 at 3:30 p.m. ET

Access and Utilization of Overdose Reversal Medications

Monday, August 10 at 3:00 p.m. ET

Excess Medications in the Home

Monday, August 17 at 3:00 p.m. ET





Thank you for joining us today!

Please refer any questions to:

matthew.rubin@faegredrinker.com

+1 202 312 7456